Compare iShares MSCI Indonesia ETF (EIDO) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Indonesia ETF vs Novavax Inc — how do they compare? iShares MSCI Indonesia ETF trades at $11.91 (market cap $409.22M), while Novavax Inc trades at $12.79 (market cap $1.82B). The key difference: Novavax Inc is far larger — about 4.4× iShares MSCI Indonesia ETF's market cap, and Novavax Inc is trading nearer its 52-week high, iShares MSCI Indonesia ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Indonesia ETF for 76 Days and Novavax Inc for 59 Days on average.
| EIDO | NVAX | |
|---|---|---|
Market Cap | $409.22M | $1.82B |
Volume | 879,527 | 6,198,505 |
52-Week High | $19.22 | $12.56 |
52-Week Low | $10.80 | $6.22 |
Typical Hold Time | 76 Days | 59 Days |
Sector | — | Health |
Enterprise Value | — | $1.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EIDO trades at $11.87, showing minimal daily movement with a 0.08% gain. Technical indicators signal a bearish trend, with moving averages and ADX pointing downward, though RSI levels hint at potential oversold conditions. Recent news highlights underperformance amid sector rotation away from Asian equities, with volume declining 21% below average. Key financial ratios are unavailable in the provided data, limiting fundamental assessment.
The outlook remains cautious due to weak price action and bearish technicals. Risks include high financials exposure and slow EPS growth. Upside may depend on seasonal trends or valuation support, but current sentiment and institutional flows suggest continued pressure. Investors should weigh technical weakness against potential bargain opportunities.
Novavax (NVAX) trades at $12.75, up 13.64% with strong technical momentum and bullish moving averages. The company shows mixed fundamentals with revenue of $1.12B in 2025 and positive net income of $440.30M, though 2026 projections indicate a return to losses. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with high volatility. Opportunities include partnership-driven growth and vaccine demand, but risks involve consistent profitability challenges, high debt-to-asset ratios, and competitive pressures. Analyst sentiment is predominantly bullish (73.9% buy ratings), yet investors should weigh the company's transition phase against financial stability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Indonesia ETF
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
